Hepion pivots to diagnostics after $9M raise; delisted, impairment and going‑concern risks

HEPION PHARMACEUTICALS, INC. (NASDAQ: HEPA)

Snapshot - what's happening inside: management has pivoted from drug development to diagnostics, sold its Rencofilstat patent assets, completed a $9.0M registered offering in Jan‑2025, in‑licensed CE‑marked diagnostics from New Day (May‑9‑2025) and recognized an impairment on that license. The company was delisted from Nasdaq in May 2025 and transitioned to the OTCQB on June 25, 2025. Management reports substantial doubt about the company's ability to continue as a going concern without additional capital and has identified material internal control weaknesses.

Key facts & figures (as reported)

* Cash at June 30, 2025: $2,924,395 (Dec 31, 2024: $406,408)

* Total assets (6/30/2025): $4,505,469

* Total liabilities (6/30/2025): $708,531 (includes derivative warrants $115,677; current notes payable $371,661)

* Stockholders' equity (6/30/2025): $3,796,938; Accumulated deficit: $(244,968,265)

* Net loss - three months ended 6/30/2025: $(1,042,572); six months: $(7,148,459)

* Loss per share - three months: $(0.09) basic & diluted; six months: $(1.00)

* Weighted-average common shares - three months: 11,328,122; six months: 7,137,017

* R&D expense - three months 6/30/2025: $423,277; six months: $445,512 (prior-year six months: $9,676,247)

* General & administrative - three months: $919,488; six months: $2,177,848

* Asset impairment recorded: $402,746 (related to New Day license)

* Cash flow (six months ended 6/30/2025): Operating cash used $(2,492,782); Financing provided $5,142,886; Net increase in cash $2,517,987

* Financing activity: Jan 23, 2025 offering gross proceeds ≈ $9,000,000; Series B cashless exercises and conversions led to large share count movements (10,173,402 Series B warrants exercised as of 6/30/2025)

* Major transactions: May 9, 2025 License Agreement with New Day - cash paid $525,000 + $270,629 in stock; total consideration allocated $815,045; $412,299 allocated to IPR&D and expensed. May 26, 2025 sale of Rencofilstat patents to Panetta (nominal cash consideration) with CVR milestones ($500k FDA approval; $1M at >$350M sales; $3M at >$750M sales).

Positive aspects (income statement & near‑term position)

* Cash improved materially in H1‑2025 (from $406k to $2.9M) after the $9.0M offering - short‑term runway extended.

* Operating expenses declined sharply vs prior year because clinical programs were wound down: six‑month R&D fell from $9.7M to $0.45M, and G&A fell from $4.0M to $2.18M.

* Working capital turned positive: working capital reported $3.9M at 6/30/2025 (improved from a deficit Dec‑31‑2024).

Negative aspects (income statement & risks)

* No revenue to date; revenue remains $0 for the periods presented - newly licensed CE‑marked products are not approved for U.S. sales.

* Significant recurring losses: six‑month net loss $(7.15M); accumulated deficit $245.0M.

* Non‑cash volatility: large fair value swings in derivatives/contingent consideration affected income (change in fair value was a $(4.1M) charge for H1‑2025 compared with a $6.46M gain prior year), making results lumpy and unpredictable.

* Impairment of in‑licensed assets ($402,746) immediately hit the P&L - management expects uncertain near‑term recoverability and noted trigger events (delayed timing to market).

* Corporate governance/controls issues: material weaknesses in internal control over financial reporting were identified and remain unremediated pending additional resources.

* Capital and listing risks: delisting from Nasdaq (suspended May 13, 2025) and move to OTCQB increases liquidity and perception risk; company states substantial doubt about continuing as a going concern without more capital.

What this means for investors

* The company has reduced cash burn by stopping clinical programs and pivoting to diagnostic assets, but it still has no revenue and a large accumulated deficit - outcomes depend on successful commercialization of licensed diagnostics, additional financing, or milestone recoveries from sold assets.

* Financials remain high risk: short runway without further funding, P&L exposed to non‑cash fair value items and impairments, and governance deficiencies that could affect reporting and execution.

Bottom line: Hepion (NASDAQ: HEPA) has stabilized cash via a January capital raise and cut operating spend by winding down its clinical program, but it remains unprofitable with no revenue, material accounting/control weaknesses, an impairment on newly acquired licensing assets, and a going‑concern warning. The next material events to watch are commercialization progress of the New Day diagnostics (EU markets), any further financings, remediation of control weaknesses, and realization of any contingent payments from the Rencofilstat sale.